50 major retail varieties are included in price monitoring!

On February 25, the Shaanxi Provincial Medical Insurance Bureau issued a notice on carrying out price monitoring of commonly used drugs, requiring cities (districts) to select 3 representative medical insurance designated retail pharmacies in the urban area as price monitoring points for commonly used drugs, focusing on monitoring sales.
Large, commonly used drugs by the common people, and announced 50 varieties included in monitoring for the first time, including 27 kinds of western medicines and 23 kinds of proprietary Chinese medicines
.
The best-selling varieties at the retail end are listed.
After reviewing the monitoring information table released this time, it is found that 12 of them are varieties of multinational pharmaceutical companies
.
AstraZeneca's metoprolol tartrate tablets, Bayer's nifedipine controlled-release tablets, acarbose tablets, aspirin enteric-coated tablets, Xi'an Janssen's miconazole nitrate cream, domperidone tablets, Pfizer's atorvastatin Calcium tablets, losartan potassium tablets and montelukast sodium tablets from Merck, paroxetine hydrochloride tablets from Tianjin SmithKline, glimepiride tablets from Sanofi, and Maizhiling tablets from Lida from Germany are all being monitored.
within the range
.
It is worth noting that there are many drugs that are at the forefront of the best-selling list at the retail end
.
For example, domperidone tablets, which are widely used to treat nausea and vomiting, have a combined terminal sales of nearly 1 billion yuan in Chinese public medical institutions and Chinese urban brick-and-mortar pharmacies in 2020
.
In China's urban physical pharmacy terminals, domperidone tablets are the TOP1 variety in the gastrointestinal antispasmodic, anticholinergic and gastric motility drug markets, and their sales have been far ahead for a long time.
In 2020, they will occupy nearly 65% ​​of the market share
.
In 2020, the total sales of acarbose tablets in Chinese public medical institutions and Chinese urban physical pharmacy terminals will exceed 5 billion yuan, and it is the best-selling oral hypoglycemic drug in China
.
In terms of proprietary Chinese medicines, Mayinglong Musk Hemorrhoids Ointment is the champion product of proprietary Chinese medicine hemorrhoids in urban retail pharmacies in China, with sales of nearly 280 million yuan in 2016
.
Ganmaoling Granules have been ranked first in the best-selling list of Chinese patent medicines for colds for many consecutive years
.
CR Sanjiu’s Ganmaoling Granules exceeded 2 billion yuan for the first time in 2019, becoming the first and only Chinese patent medicine brand for colds with annual sales exceeding 2 billion yuan, and sales in 2021 will be close to 2.
3 billion yuan
.
Medical insurance strengthens the control of retail drug prices In fact, relevant departments have already taken action on drug price monitoring
.
As early as December 2019, the National Medical Insurance Bureau issued the "Opinions on Doing a Good Job in Current Drug Price Management", pointing out that it is necessary to give full play to the role of medical insurance in guiding drug prices, improve the management of agreements with designated institutions, and strengthen the payment of drugs by medical insurance funds.
Price supervision and information disclosure positively guide the market price order
.
In September 2021, the "14th Five-Year Plan for National Medical Security" issued by the General Office of the State Council also proposed to strengthen the normalized supervision of the prices of drugs and medical consumables, and to implement a national medical price monitoring project
.
Specific to medical insurance pharmacies, the local level has also implemented top-level requirements and strengthened the monitoring and management of drug prices
.
On November 5, 2021, the Shenzhen Municipal Medical Security Bureau issued a notice on strengthening the monitoring and management of medical insurance drug prices in fixed-point retail pharmacies, clarifying that the country, Guangdong Province, and Shenzhen will organize the centralized procurement of selected and non-selected drugs, and the national medical insurance negotiation.
Medicines, medicines included in the management of "two diseases" (hypertension and diabetes) by the state and Guangdong Province, medicines covered by Shenzhen social medical insurance outpatient medicines for specific diseases, medicines included in the drug catalogue of Shenzhen's supplementary medical insurance for major and extraordinarily serious diseases, the city's Drugs with high unit price, large sales volume, and high total sales amount in designated retail pharmacies, anti-tumor drugs, drugs that have been subject to repeated price warnings in designated retail pharmacies, and other drugs that require key monitoring are included in key monitoring
.
This time, the Shaanxi Provincial Medical Insurance Bureau also proposed to gradually monitor the price information of retail pharmacies, use the price monitoring information to guide the market, and regulate the market order
.
On October 18 last year, the Shanghai Sunshine Pharmaceutical Purchasing Network issued the "Notice on Announcement of the Operational Measures for the Administration of Drug Prices in Designated Pharmacies in this City", pointing out that the sales of medicines in the medical insurance catalogue by designated pharmacies must pass the "Shanghai Pharmaceutical Purchasing Service and Supervision Information System" ( Hereinafter referred to as “Sunshine Platform”) upload retail price information, and request the designated pharmacies to upload the retail price independently and fill in the effective date of the price according to the information pushed by the Sunshine Platform and the “red and yellow reminder line”, in combination with the relevant stipulations in the medical insurance service agreement of the designated pharmacy
.
It is worth noting that the pharmacy has established a price "red and yellow line" monitoring and early warning mechanism by referring to the relevant provisions of the designated pharmacy medical insurance service agreement, and referring to the designated medical institutions to purchase the same product with the same product specification or the same generic name drug price and other information.
"Red and yellow prompt line" information, pushed by the Sunshine platform
.
In this regard, industry insiders said that the policy is gradually tightening.
For designated pharmacies with medical insurance drug sales accounting for about 50%, the price "red and yellow lines" are in line with the hospital, which further restricts the drug pricing power of designated pharmacies.
The price may be further reduced, and it will be strictly controlled by the regulatory authorities, which will have a big impact on the gross profit of pharmacies
.
As China's pharmaceutical prices gradually move towards a "game of chess" situation, retail pharmacies are bound to be unable to survive alone
.
Under the background of the medical insurance bureau as a major payer, it is impossible for out-of-hospital retail channels to return to the era of "high-margin" and "high-priced drugs".
Low gross profit tests cost control, and out-of-hospital prescriptions call for quality services.
Under the high pressure of regulation and supervision, the industry reshuffle of retail chain pharmacies is coming quietly
.